


Alliance A11104/ACRIN 6694:
Effect of Preoperative Breast MRI on
Surgical Outcomes, Costs and Quality
of Life of Women with Breast Cancer

Isabelle Bedrosian, MD
UT M.D. Anderson Cancer
Center

Breast MRI detection of additional areas of cancer

- Meta-analysis of 19 studies, 2610 women
- Additional foci of disease detected by MRI only in 16% (6-34%)
- MRI altered surgical therapy in 7.8-33% of women

MRI and detection of contralateral breast cancer (ACRIN 6667)



Lehman, NEJM, 2007


Does preoperative breast MRI have clinical utility?

- Appropriate selection for BCT
 - Reduce rates of re-excision
 - Reducing rates of conversion to mastectomy
- Decrease rates of local failure
- Decrease contralateral breast cancer rates

MRI and re-excision rates

- COMICE trial (UK)
 - Prospective randomized trial
 - MRI: 816, no MRI: 807
 - Primary endpoint
 - Reduction in re-operation rates in MRI arm
 - No difference in re-operation rates (18.75% vs. 19.33%)

Impact of MR on Local Recurrence



Solin, JCO, 2008

Probability of contralateral breast cancer

MRI ¹	Occult ² (CPM)	U Penn ³	SEER ⁴
3.1%	5%	6% at 8 years for both MRI and no MRI cohorts	3% at 5yrs

0.6-0.75%/year

1. Lehman, NEJM, 2007
2. Boughey, Cancer 2006

3. Solin, JCO, 2008
4. Gao, IJROBP, 2003

Does preoperative breast MRI have clinical utility?

- Reduce re-operation rates
 - MRI does not improve margin negative rates at first excision
- Reduce local recurrence rate
 - Retrospective data-mixed results
- Reduce contralateral breast cancer rate
 - Significance of MRI detected contralateral breast cancer?

Limitations to current data

- Paucity of studies
- Only 1 prospective trial (COMICE)
 - Did not control for MR quality and interpretation or MRI findings
- Does not incorporate tumor biology

Tumor subtype and local recurrence rate following BCT


	ER +		ER -	
	ER or PR+, her-2 -	ER or PR +, her-2 +	ER/PR -, her-2 +	ER/PR/ Her-2 -
LR rate at 5 years	0.8%	1.5%	8.4%	7.1%

Nguyen et al, JCO 2008

Impact of PMRT on Outcomes by Subtype

HR +

HR -




Rationale

- Breast MRI may be particularly important for ER/PR negative disease which is shown to be relatively radioresistant with higher rates of local failure after BCT
 - Detecting and surgically removing additional foci of disease may be particularly important for this group of patients.

Hypothesis

Preoperative breast MRI improves staging and selection of patients with ER/PR negative tumors for BCT, thus lowering rates of local regional recurrence.

Alliance A11104 Phase III trial



Sample size: 244 patients/arm

Eligibility criteria

- Women with
 - ER/PR <10%
 - Any Her2
- Stage I-II, unilateral cancer
- No previous breast cancer history
- No preoperative chemotherapy
- No plans for partial breast irradiation following lumpectomy
- No known BRCA carriers
- No previous breast MRI within prior 12 months

Trial endpoints

- Primary
 - LRR rates at 5 years between the MRI and no MRI arm
- Secondary
 - Rates of re-excision, including conversion to mastectomy
 - Contralateral breast cancer rates
 - Time to local recurrence
 - Overall and disease specific survival
 - MRI technical performance (sensitivity, specificity, PPV)


Correlatives

Study	Requirement	Material request
Medical care costs	Required	CRFs with patient status and test data
QOL	Required	questionnaire
Molecular predictors	optional	Tissue


FAQs

- **BRCA testing**
 - Not required to enroll
 - If pt referred for testing, can still enroll into trial. If later found to be BRCA +, can come off study.
- **MRI reimbursement**
 - For patients randomized to MRI arm, additional \$900 will be paid by ACRIN to support image data collection and transmission
 - MRI can be billed to insurance as per institutional guidelines/standards
- **Is prior history of contralateral breast cancer an exclusion?**
 - Yes
- **Can Spanish speaking patients enroll?**
 - Yes, Spanish forms available for all aspects EXCEPT "Assessment of Survivor Concerns" form which will require translation to patient
- **Is there a patient education brochure?**
 - Yes, available on Alliance website (and will be on CTSU soon)

Current Status



Monthly Accrual



Questions	Contact
Patient Eligibility, Treatment	Isabelle Bedrosian ibedrosian@mdanderson.org Heather Becker hpbecker@uchicago.edu
Data Submission, RAVE or Follow-up	Amy Oeltjen oeltjen.amy@mayo.edu
IRB Issues, Model Consent Revisions, and AdEERS Reporting	Regulatory Affairs Manager E-mail: regulatory@alliancencn.org
ACRIN accreditation, image acquisition, radiology data reporting	Sharon Mallett smallett@acr.org

Monthly CRA calls: 1st Thursday of month, 11:30 CST